Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ:EVO)

3.510 -0.010 (-0.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 Next >
Evotec Presents Sustainability Strategy
Via ACCESSWIRE
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Via ACCESSWIRE
Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz
Via ACCESSWIRE
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
Via ACCESSWIRE
Evotec SE Provides Update on Cyber Attack
Via ACCESSWIRE
Evotec and TIAP Expand LAB150 BRIDGE Partnership to Include Amgen
Via ACCESSWIRE
Cyber Attack on Evotec
Via ACCESSWIRE
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Via ACCESSWIRE
Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
Via ACCESSWIRE
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
Via ACCESSWIRE
Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
Via ACCESSWIRE
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Sernova Corp. (TSX: SVA) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
Evotec Receives € 150 m Loan from European Investment Bank
Via ACCESSWIRE
Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership
Via ACCESSWIRE
Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
Via ACCESSWIRE
Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies
Via ACCESSWIRE
Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE Reports Results for the First Nine Months 2022 and Provides Corporate Update
Via ACCESSWIRE
Evotec SE to Announce Results for the First Nine Months 2022 on 09 November 2022
Via ACCESSWIRE
Evotec Completes Acquisition of Central Glass Germany
Via ACCESSWIRE
Evotec Presents Paradigm Shift in Biologics at Capital Markets Day
Via ACCESSWIRE
Evotec, CDP Venture Capital and Angelini Ventures Launch Translational Partnership 'Extend' with Leading Italian Academic Institutions
Via ACCESSWIRE
Evotec Enters Partnership with Hannover Medical School to Create Molecular Patient Database in Autoimmune Diseases
Via ACCESSWIRE
Evotec launches PanOmics Data Analysis Platform PanHunter at Bio-IT World
Via ACCESSWIRE
TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
From Toronto Innovation Acceleration Partners
Via Business Wire
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
Via ACCESSWIRE
Evotec Initiates Ground-Breaking for New Biologics Facility J.POD(R) Toulouse, France (EU)
Via ACCESSWIRE
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
Via ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2022 and Provides Corporate Updates
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.